Insider trade

Director sold ~$556K of UTHR shares in the open market

Traded Dec 22, 2025 · Filed Dec 24, 2025

~$556K
Approx. value · 1,087 sh @ $511.22: 4,863
Holds after · shares reported: +5.4%
Since filing · from the first close after the filing, $513.79 → $541.62 on Oct 6, S&P 500 +13.8%

Why it stands out

A United Therapeutics director sold $556K of United Therapeutics shares. The filing does not indicate a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

DirectorIndirect holding$500K–$1M

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$555,700

Shares × reported transaction price

Timing vs results

54 days after results of Oct 29, 2025, 65 days before results of Feb 25, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.3%	−1.2%	−4.1%
30 days	−8.9%	−0.2%	−8.7%
90 days	+3.3%	−5.4%	+8.7%
180 days	+4.6%	+7.8%	−3.2%

Past results only. Not a forecast.

This transaction was executed in multiple trades at prices ranging from $510.64 to $511.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.

Planned saleFiled 9mo ago

Filed 9mo ago

Traded Jan 15 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

Planned saleFiled 9mo ago